Sustainability Plan

The Sustainability Plan is the tool used to share the Group’s future trajectory with its stakeholders: it represents an expression of the ambitions of the Recordati group and the commitments it wishes to prioritise in order to promote sustainable and responsible growth.

Growth and achievement of challenging business and sustainability goals are not incompatible: on the contrary, Recordati is convinced that responsible actions and the generation of shared value contribute to the long-term success of the Company.

Improving people’s health and quality of life is the basis of our mission: it is part of our DNA. Recordati’s People have always given their utmost every day to pursue this goal.

As emphasised by the World Health Organization (WHO), health is not merely the absence of disease or infirmity, but a state of complete physical, mental and social well-being. To improve health, it is therefore necessary to intervene on a number of determining factors, such as the social, physical and economic conditions under which people are born, live and work, including healthcare systems. In this context, in addition to institutions and governments, pharmaceutical companies must also develop strategies for the improvement of the healthcare system, in terms of availability, accessibility and quality of healthcare structures and the goods and services provided.

We are living in a rapidly changing world that often raises concerns about sustainability for future generations. The current scenario in which we live has led us to reflect deeply on the relationship between humanity and nature and on the importance of an overall balance: the well-being and health of people and the health of the planet are closely connected. We cannot be healthy in an unhealthy environment and with no health there is no wealth and no social equity.

With this systemic approach and in accordance with the 2030 Agenda for Sustainable Development priorities, we wish to contribute to supporting global development, promoting human well-being and protecting the environment.

 

We want to continue to do our part.

Patient Care

Our ambition We are open to partnering and dedicated to discovering and developing innovative, value-added products that improve quality of life and help people to enjoy longer, healthier and more productive lives. We wish to offer our patients fast, widespread and sustainable access to our products.

People Care

Our ambition We are committed to creating a safe and inclusive working environment where everyone can express their talents. Our Employees are our most important asset and, therefore, we recognise and value the role that each person plays in the success of our business. We aim to create shared value and positively contribute to sustainable development where we operate, aware of the importance of dialogue, collaboration and respect for the community.

Environmental Protection

Our ambition Improving human health is the cornerstone of our mission, but we are aware that the health and well-being of present and future generations and the health of our planet are closely interlinked. With this in mind, we want to take conscious action by working to preserve natural resources and biodiversity and contribute to the fight against climate change by minimising our environmental impact.

Responsible Sourcing

Our ambition We want to build relationships based on transparency and trust, sharing our values with suppliers and strategic partners. We are committed to constantly promoting respect for ethical, environmental and social aspects along the entire value chain.

Ethics and Integrity

Integrity is our founding value, and we lead by example.
The principles of honesty and transparency towards our Shareholders
and Stakeholders guide our daily actions.

The Sustainability Plan, defined in accordance with the materiality analysis, also highlights the contribution to the achievement of 10 of the 17 Sustainable Development Goals (SDGs) of the 2030 Agenda, the common goals signed by UN member states that outline a path of collaboration and responsibility to confront today’s complex challenges.

Process for the definition of the Sustainability Plan

The objectives of the CEO’s MBO scheme include the key social and environmental targets defined in the Sustainability Plan. Furthermore, responsibility for the achievement of the goals included in the Sustainability Plan is assigned to the representatives of the various departments involved, who have the resources, tools and know-how required for their implementation; the Management by Objectives (MBO) scheme integrates social and environmental objectives associated with the implementation of the Plan itself which are assigned to certain key management figures.

Ethics and Integrity – Future Targets [SDG 16]

Business ethics, integrity and anti-corruption

 

100% of Group employees involved in a two-year training programme on ethics, anticorruption, anti-bribery topics (2022 – 2023)

Patient Care – Future Targets [SDGs 3 – 9]1

Access to medicine and healthcare

 

Recordati believes that every single patient should have access to the best possible treatment.

 

In the field of rare diseases, the Group is committed to:

 

  • Continuing with Patient Assistance Program (PAP), Co-Pay Assistance Program (CAP) or similar programs aimed at providing assistance to patients who are eligible to receive financial support for products (2023)

 

  • Continuing to work closely with rare disease communities (including doctors, healthcare professionals, patients groups and families) to increase awareness, improve diagnosis and expand availability of treatments for people with rare diseases (2023)

 

  • Continuing to expand rare disease and orphan drugs innovation pipeline and R&D of new therapies (2023)

 

In the context of the Specialty & Primary Care Division, the Group is committed to:

 

  • Continuing to invest in our plant in Tunisia to be able to continue providing high-quality and affordable products servicing a broad range of therapeutic areas including low- and middle-income Countries (Tunisia, Sub-Saharan Africa) (2023).

 

Continue initiatives of product donations to organisations that collect and distribute pharmaceuticals to disadvantaged people (2023)




1. the table relating to the Group’s commitments to its patients shows only some of the targets. Commitments regarding quality, product safety, research and development, etc. are intrinsically related to the business and are thus ongoing. More details on the Group’s development plans are included in the Financial Statements.

People Care – Future Targets [SDGs 3 – 4 – 5 – 8]

Talent attraction and development

 

On the base of Key Value Driving Roles Matrix define Development and/or Retention Plan for the Successors, Key Resources, Talents and Critical Resources identified on the Matrix that at least once per year have to be discussed and agreed among the ELT (Executive Leadership Team) (2023).

 

Strengthening university engagement initiatives to promote the attraction of talent (2023)

 

Diversity and equal opportunities

 

Grant equal opportunities to all genders at all levels and progressively increase the percentage of women in Top and Senior management positions by promoting initiatives, including:

 

  • Recruit and promote employees who have both top skills and qualifications and reflect our focus on inclusion and diversity: from 2022 onwards, at least 40% of candidates short-listed for Top and Senior Management positions must be women and the internal personnel responsible for selecting new recruits and promoting employees must include at least one woman

 

  • Launch a mentorship initiative on D&I (2023)

 

Engagement

 

Seek employee feedback and measure evolution of engagement through the launch of an “Employee Opinion Survey” to all employees (2023).

 

Health, safety and well-being

 

Run an on-line driver safety training programme for all employees with a company car in order to encourage safe driving behaviors (2022- 2023)

 

Support for local communities

 

Continue to support the communities through solidarity, social and cultural initiatives aimed at promoting the growth and wellbeing of local communities (2023)

 

Launch of employee volunteering initiatives (2023)

Environmental Protection – Future Targets [SDGs 6 – 7 – 12 –13]

Climate action – renewable energy initiatives

 

100% renewable electricity purchased for our Group  production and packaging sites and annexed offices (2025)1

 

Finalization of feasibility studies for installing additional renewable energy production systems at the following plants: Italy (Campoverde), Ireland, Tunisia, Türkiye (2023).

 

Climate action – energy efficiency initiatives

 

Gradually replace traditional lighting systems with LED lights: complete replacement in the production department of the Milan plant by 2023

 

Climate action – other initiatives

 

Planting of about 11,250 trees in the Milan Metropolitan area (and maintenance for 5 years) through the support of the Forestami project for the three-year period 2021- 2023

 

Responsible waste management and circular economy initiatives

 

Continue with the analysis of possible new initiatives for the recovery and reuse of chemical raw materials used in production processes, and investigate further the possibility of recovering certain raw materials on a routine basis for which feasibility on an industrial scale has already been demonstrated (2022 – 2023)

 

Continue with the analysis of possible packaging solutions with lower environmental impact (2022- 2023)

 

1. Purchase of renewable electricity for plants located in countries where it is available.

Responsible Sourcing – Future Targets [SDGs 8 – 9]

Promote a responsible supply chain

 

  • Monitoring of suppliers on ESG aspects through assessment (desk audit) by an independent third party (EcoVadis): performance of 160 assessments (desk audits) by 20241

 

  • Engagement initiatives for suppliers that received lower scores in the assessment to promote and increase awareness of ESG aspects (2023)

For more information please see the Consolidated

Non-Financial Statement 2022

Leaving Recordati.co.uk

You are now leaving this site, a corporate Recordati website, and are being redirected to url.

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to support.microsoft.com

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to clinicaltrials.gov

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to hpra.ie

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to yellowcard.mhra.gov.uk

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to search.disclosureuk.org.uk

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to support.apple.com

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to support.mozilla.org

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to support.google.com

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to youronlinechoices.com

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to edpb.europa.eu

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to edoeb.admin.ch

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to ico.org.uk

Leaving recordatirarediseases.co.uk

You are now leaving this site, a corporate Recordati Rare Diseases website, and are being redirected to careers.recordati.com

Recordati for the planet
A clean environment is essential for people’s well-being: the health of the planet and the health of people is tightly interconnected. Environmental elements, such as air, water, land and climate, all have an impact on the well-being of humans. Placing a focus on people’s health and being sustainable therefore also means prioritising environmental protection and a responsibility towards future generations. This is why the Group ensures that it conducts business in a socially responsible manner and in accordance with sustainable practices, national and international laws, and the expectations of stakeholders.
Recordati for the community
We believe that contributing to the well-being of the community and dedicating part of our resources to acts of solidarity is not merely the fulfilment of company obligations or professional duty, but rather a moral imperative, an essential part of a healthy business capable of growth but at the same time able to support and develop the community in which it operates and make its employees proud.
Value and diversity of our people
At Recordati, we believe in equal opportunities and we guarantee that everyone can achieve their potential. We see diversity as a value and will not tolerate any discrimination based on ethnicity, nationality, gender, sexual orientation, disability, age, political or religious belief, or any other personal characteristics. At Recordati, we work hard to create a safe and inclusive work environment, where we all have our rights to physical and psychological integrity respected on a daily basis, as well as our right to freedom of opinion and association. We recognise that we each have a role to play in the success of our business and we implement staff development policies through which everyone’s contribution and achievements can be appropriately rewarded.
Multiple opportunities
Recordati is uniquely structured to bring treatment options across specialty and primary care, consumer healthcare, and rare diseases. We have fully integrated operations across research and development, chemical and finished product manufacturing through to commercialisation and licensing.
Luigi Longinotti
Managing Director and General Manager EMEA

Luigi Longinotti is Managing Director and General Manager for EMEA at Recordati Rare Diseases, leading the European and Middle Eastern Commercial Operations. He is responsible for Marketing, Medical, Market Access, Regulatory, Manufacturing and Logistics, as well as the enabling functions to support the business, including Compliance and Quality.

 

He joined Recordati in July 2014 as Corporate Portfolio Management Director for Orphan Drugs. In such a role he has been responsible for driving the growth of the rare disease portfolio at Recordati, with his duties ranging from business development to strategic marketing and pipeline project management.

 

Before he joined Recordati, he held senior business and corporate development roles at Chiesi Farmaceutici and Menarini Group where he executed several key asset deals and transactions.

Luigi gained a degree in Economics from the University of Florence and a Master’s degree in Business Innovation from Sant’Anna School of Advanced Studies in Pisa.

Bruno Parenti
Head of LAC Region, Head of Global Endocrinology Franchise

Bruno Parenti is Head of LAC Region at Recordati Rare Diseases, leading the business in Latin America, Asia Pacific and Russia. He has been in this position since 2011, where he spearheaded the expansion of operations around the globe. He recently assumed the additional role of Head of Global Endocrinology Franchise, establishing the new HQ in Basel and building a dedicated organization.

 

Prior to these positions, Bruno spent two years at Recordati Ireland overseeing international sales in the Asia-Pacific region. He served at Chiesi Farmaceutici for two years as Area Manager for the Far East. Earlier in his career, he held commercial roles at Kedrion Biopharmaceuticals where he was responsible for international markets with a focus on Latin America and the Middle East.

Mohamed Ladha
President and General Manager, North America

Mohamed Ladha is the President and General Manager at Recordati Rare Diseases where he is   responsible for the US and Canadian business. During his career,  Mohamed has held numerous leadership positions globally in hematology/oncology and specialty care to oversee business in the US, Canada, EU, China, Emerging Markets, and Japan.

 

Mohamed  joins Recordati Rare Diseases from Oncopeptides, where he was the General Manager and Executive Vice President for the US Region Business Unit. Prior to Oncopeptides, he served in a series of leadership positions of increasing responsibility at companies including Vertex Pharmaceuticals, Pfizer, Schering-Plough, Merck & Company, Hospira, ARIAD Pharmaceuticals, Takeda Oncology, and Tocagen. He started his career in basic science research focused in oncology at the Dana-Farber Cancer Institute.

 

Mohamed graduated from Hampshire College with a Bachelor of Arts degree. He also holds professional/graduate degrees from Harvard University’s Kennedy School of Government and Northwestern University’s Kellogg School of Management.

 

Changing to first name to be consistent with bio below, also feel that first name as opposed to Mr has a more informal and friendly tone.   [EC1]

Scott Pescatore
Executive Vice President

Scott Pescatore is Vice President and Head of Global Operations at Recordati Rare Diseases.

He holds a Doctor of Pharmacy degree and completed his post-doctoral fellowship in Pharmacology and Drug Development. Dr Pescatore has spent over 20 years working internationally in the pharmaceutical industry, specializing in oncology, haematology and rare diseases.

 

He joined Novartis Oncology US in 2001 where he served in various medical, sales and marketing roles of increasing responsibility. In 2008, he moved to Novartis Oncology UK as Business Franchise Head for solid tumours where he also managed the New Products portfolio. In 2010 he moved to Milan to manage the Region Europe Haematology Franchise where he led the joint venture between Novartis Oncology and Incyte to launch a novel treatment for myeloproliferative disorders. In 2014 he was appointed the Oncology General Manager in Ireland and after three years returned to Milan as General Manager of the Region Europe Rare Disease Business Unit, overseeing operations in 37 markets and focusing on the endocrinology portfolio.

 

Prior to joining Recordati Rare Diseases in 2020, he was Vice President Oncology Business Unit for AstraZeneca Italy where he was responsible for the portfolio of oncology/haematology products including two joint ventures with MSD and Daiichi Sankyo.

You are about to leave this site and visit the recordati global website?

To continue please click the link below.